SERB Pharmaceuticals has acquired exclusive rights to develop and sell Idefirix (imlifidase), a treatment for highly sensitised kidney transplant patients, across Europe and the MENA region from Hansa Biopharma for €115 million. Idefirix helps reduce antibodies that cause organ rejection, addressing a critical need for patients who face long waits for compatible kidney transplants. The deal includes upfront and milestone payments to Hansa, with SERB taking over regulatory filings and ongoing studies. This acquisition expands SERB's portfolio in rare and urgent medical conditions and aims to improve transplant access for underserved patients.
Strategy, a major Bitcoin treasury, added 24,869 BTC worth about $2 billion, raising its total holdings to 843,738 BTC. This purchase occurred near their average cost basis, suggesting a psychologically important price zone that may indicate a local ...
ONWARD Medical, a leader in neurotechnology for spinal cord injury therapies, will announce its first quarter 2026 financial results on May 26, 2026. CEO Dave Marver will host a webcast to provide a detailed business update. The company is known for ...
KITE led Upbit's crypto greed index with a score of 76 despite a 5.04% price drop to 339 won, signaling a cooling phase rather than a trend reversal. The token saw heavy trading volume (~15.06 billion won), indicating active repositioning amid sustai...
European stocks are set to open mixed following U.S. President Trump's announcement to postpone a planned attack on Iran after diplomatic requests from Middle Eastern leaders. Oil prices dropped, with Brent crude down over 2%, reflecting eased geopol...
XRP is consolidating near $1.30 after a three-day selloff, with traders closely monitoring if it can hold this critical support level. A breakdown below $1.30 could lead to further declines, while recovery depends on Bitcoin's stabilization and incre...
